{
  "actions": [
    {
      "acted_at": "2005-06-08T14:45:00-04:00", 
      "references": [
        {
          "reference": "CR H4243-4244", 
          "type": "consideration"
        }, 
        {
          "reference": "CR H4243", 
          "type": "text"
        }
      ], 
      "text": "Amendment (A010) offered by Mr. Hinchey.", 
      "type": "action"
    }, 
    {
      "acted_at": "2005-06-08T14:52:00-04:00", 
      "references": [], 
      "text": "Mr. Bonilla raised a point of order against the Hinchey amendment (A010). Mr. Bonilla stated that the provisions of the Hinchey amendment seek to change existing law and constitute legislation in an appropriations bill. The Chair sustained the point of order.", 
      "type": "action"
    }
  ], 
  "amendment_id": "hamdt233-109", 
  "amendment_type": "hamdt", 
  "amends_amendment": null, 
  "amends_bill": {
    "bill_id": "hr2744-109", 
    "bill_type": "hr", 
    "congress": 109, 
    "number": 2744
  }, 
  "amends_treaty": null, 
  "chamber": "h", 
  "congress": "109", 
  "description": null, 
  "house_number": 10, 
  "introduced_at": "2005-06-08", 
  "number": 233, 
  "purpose": "An amendment to insert a new section providing authority for the Secretary to require that the manufacturer of an approved drug conduct one or more studies to confirm or refute an empirical or theoretical hypothesis of a significant safety issue with the drug.", 
  "sponsor": {
    "district": "22", 
    "name": "Hinchey, Maurice D.", 
    "state": "NY", 
    "thomas_id": "00541", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "offered", 
  "status_at": "2005-06-08", 
  "updated_at": "2013-07-17T08:16:18-04:00"
}